KBP-336
KBP-336 is a dual amylin and calcitonin receptor agonist (DACRA). KBP-336 exhibits antidiabetic and insulin-sensitizing properties, improves glucose levels, spatial learning, and memory in diabetic rats, and reduces blood glucose. KBP-336 also alleviates pain-like symptoms in osteoarthritis rats. KBP-336 also promotes weight and fat reduction. KBP-336 is useful for research on diabetes, obesity, and arthritis.
For research use only. We do not sell to patients.
- Formula: C172H287N43O56S2
- Molecular Weight:3917.50
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
-
Biological Activity
-
Chemical Information
- Purity & Documentation
- References
-
Help & FAQs
Biological Activity
KBP-336 (0.5-4.5 nmol/kg; subcutaneous injection; every 72 hours; 6-8 weeks) alleviates pain-like symptoms and reduces body weight and adipose tissue in rats with high-fat diet-induced obesity combined with medial meniscectomy[2].
KBP-336 (4.5 nmol/kg; subcutaneous injection; once every 3 days; 8 weeks) exhibits anti-obesity activity in high-fat diet-induced obese rats[3].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Zucker Diabetic Fatty Rats (male, 6-7 weeks old, fed Purina Laboratory Diet #5008, left untreated for 3 weeks to develop diabetes)[1]
-
Dosage:4.5 nmol/kg
-
Administration:s.c.; every 3 days; 127 days
-
Result:Significantly improved spatial learning.
Improved fasting blood glucose levels, reduced tAUC of fasting blood glucose and improved HbA1c levels.
Improved glucose tolerance, preserved plasma insulin levels and prevented eye cataract development.
-
Animal Model:Sprague Dawley rats (high-fat diet-fed with medial meniscectomy)[2]
-
Dosage:0.5 nmol/kg; 1.5 nmol/kg; 4.5 nmol/kg
-
Administration:s.c.; every 72 hours; 6 and 8 weeks
-
Result:Significantly increased the 50% paw withdrawal threshold (PWT), indicating relieved pain-like symptoms.
Induced significant weight loss and reduced inguinal and perirenal adipose tissue masses at doses of 1.5 and 4.5 nmol/kg.
Did not affect body weight or fat depots, still effectively alleviated pain at 0.5 nmol/kg dose.
-
Animal Model:Sprague-Dawley rats (male, 5-6 weeks, high-fat diet)[3]
-
Dosage:4.5 nmol/kg
-
Administration:s.c.; every 3 days; 8 weeks
-
Result:Significantly reduced body weight and adiposity, improved glucose homeostasis, delayed gastric emptying.
Increased oligomycininduced leak respiration and the activity of citrate synthase and β-hydroxyacetyl-CoA-dehydrogenase.
Chemical Information
-
Molecular Weight 3917.50
-
Formula C172H287N43O56S2
-
Sequence
Ac-Cys-Ala-Ser-Leu-Ser-Thr-Cys-{Aib}-Leu-Gly-Arg-Leu-Ser-Ala-Glu-Leu-His-Lys(AEEA-AEEA-γGlu-C18 diacid)-Ala-Thr-Tyr-Pro-Lys-Thr-Asp-Val-Gly-Ala-Asn-Ala-Pro-NH2
-
Sequence Shortening
Ac-CASLSTC-{Aib}-LGRLSAELH-Lys(AEEA-AEEA-γGlu-C18 diacid)-ATYPKTDVGANAP-NH2
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Purity & Documentation
References
[1]. Petersen EA, et al. DACRA induces profound weight loss, satiety control, and increased mitochondrial respiratory capacity in adipose tissue. Int J Obes (Lond). 2024 Oct;48(10):1421-1429. [Content Brief]
[2]. Larsen AT, et al. The Insulin Sensitizer KBP-336 Prevents Diabetes-Induced Cognitive decline in ZDF Rats. J Prev Alzheimers Dis. 2024;11(4):1122-1131. [Content Brief]
[3]. Mohamed KE, et al. The dual amylin and calcitonin receptor agonist KBP-336 elicits a unique combination of weight loss, antinociception and bone protection - a novel disease-modifying osteoarthritis drug. Arthritis Res Ther. 2024;26(1):129. Published 2024 Jul 12. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Powered by Bioz